Mirati Therapeutics, Inc., incorporated under the laws of the State of Delaware on April 29, 2013, is a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted oncology products. The Company focuses its development plans on drugs for the treatment of specific subpopulations of cancer patients to meet their needs. The company's pipeline consists of three product candidates: MGCD 265, MGCD 516 and mocetinostat. MGCD 265 and MGCD 516 are oral biotypes, multi-target kinase inhibitors currently in development for the treatment of patients with non-small cell lung cancer, head and neck squamous cell carcinoma and other solid tumors. MGCD 265 is currently in Phase 1/2 clinical development and MGCD 516 is in advanced preclinical development, and its first clinical phase is expected to begin in the first half of 2014. Mocetinostat is an oral biotype drug, a spectral selective histone deacetylase, an inhibitor that can treat first-line myelodysplastic syndromes. The company is planning to launch a Phase 3 clinical trial of mocetinostat by the end of 2014. In addition, it causes lymphoma or solid tumors in two clinical study patients whose tumors were found to have genetic alterations in preclinical models, and tumor cells showed greater sensitivity to mocetinostat. 

MRTX(Delisted)